Myelodysplastic syndromes


NICE Appraisal

TA128 Azacitidine for the treatment of myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia

DSU Reports

Myelodysplastic syndromes – azacitidine: Review of Celgene’s response to the post-appeal ACD (December 2010)

Addendum to the September 2010 report by the Decision Support Unit (October 2010)

Myelodysplastic syndromes – Azacitidine: A critical appraisal of additional evidence submitted by Celgene and the MDS Foundation (September 2010)

Azacitidine STA Economic Model (September 2009)

DSU response to manufacturer’s revised model (December 2009)